0
0
Read Time:10 Second
Glenmark Pharmaceuticals has entered into an exclusive agreement with Hengrui Pharma for Trastuzumab Rezetecan (SHRA1811), a nextgeneration HER2targeting antibody drug conjugate. Under the pact, Glenmark will have exclusive rights to develop and…
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %